Saltar al contenido
Merck

Assembly and activation of the Hippo signalome by FAT1 tumor suppressor.

Nature communications (2018-07-10)
Daniel Martin, Maria S Degese, Lynn Vitale-Cross, Ramiro Iglesias-Bartolome, Juan Luis Callejas Valera, Zhiyong Wang, Xiaodong Feng, Huwate Yeerna, Vachan Vadmal, Toshiro Moroishi, Rick F Thorne, Moraima Zaida, Bradford Siegele, Sok C Cheong, Alfredo A Molinolo, Yardena Samuels, Pablo Tamayo, Kun Liang Guan, Scott M Lippman, J Guy Lyons, J Silvio Gutkind
RESUMEN

Dysregulation of the Hippo signaling pathway and the consequent YAP1 activation is a frequent event in human malignancies, yet the underlying molecular mechanisms are still poorly understood. A pancancer analysis of core Hippo kinases and their candidate regulating molecules revealed few alterations in the canonical Hippo pathway, but very frequent genetic alterations in the FAT family of atypical cadherins. By focusing on head and neck squamous cell carcinoma (HNSCC), which displays frequent FAT1 alterations (29.8%), we provide evidence that FAT1 functional loss results in YAP1 activation. Mechanistically, we found that FAT1 assembles a multimeric Hippo signaling complex (signalome), resulting in activation of core Hippo kinases by TAOKs and consequent YAP1 inactivation. We also show that unrestrained YAP1 acts as an oncogenic driver in HNSCC, and that targeting YAP1 may represent an attractive precision therapeutic option for cancers harboring genomic alterations in the FAT1 tumor suppressor genes.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Medio de Eagle modificado de Dulbecco, glucosa elevada, With 4500 mg/L glucose, L-glutamine, sodium pyruvate, and sodium bicarbonate, liquid, sterile-filtered, suitable for cell culture
Sigma-Aldrich
D-Lysine, ≥98% (HPLC)